Italy reconvenes CUD medical devices commission
This article was originally published in Clinica
Executive Summary
Italy has reconvened, until July 2010, the medical devices commission (CUD). The February 7 decree establishing its second renewal since 2002 has not changed its remit since taking on the "advisory" roles imposed in its first renewal in 2005. These feature the initiatives launched in 2007 to reclassify the devices available for use by the national health system (SSN), against new reference prices (see Clinica No 1286, p 3). The CUD's core competencies are to direct all national healthcare technology assessment, market regulation, product registration, surveillance and quality R&D activities.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.